Margo Breilyn
Clinical Genetics (M.D.) · Bronx, NYNPI 1932593464
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,245 of the $7,898 with a category attached, or 79.1%. Biomarin Pharmaceutical Inc. accounts for 73.7% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $5,849, more than ten times the $30 reported in 2022.
Across 18 payments — averaging $438.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biomarin Pharmaceutical Inc.$6K
- Modernatx, Inc.$2K
- PTC Therapeutics, Inc.$60
- Mirum Pharmaceuticals, Inc.$45
- Ultragenyx Pharmaceutical Inc.$30
Across 91 payments — averaging $12,308 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$735K
- Ultragenyx Pharmaceutical Inc.$224K
- PTC Therapeutics, Inc.$136K
- Recordati_rare_diseases_inc.$26K
What the payments were for
- Consulting fees$6,24579%
- Travel & lodging$1,21015%
- Food & beverage$4135%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biomarin Pharmaceutical Inc. | 13 | $5,823 |
| Modernatx, Inc. | 1 | $1,940 |
| PTC Therapeutics, Inc. | 1 | $60 |
| Mirum Pharmaceuticals, Inc. | 2 | $45 |
| Ultragenyx Pharmaceutical Inc. | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Palynziq$5,618
How this compares
$7,898 in reported general payments places this provider in the 75th percentile of 49 clinical genetics (m.d.) providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RavictiGlycerol Phenylbutyrate | 26 | $2,338,402 |
| PalynziqPegvaliase-Pqpz | 13 | $493,295 |
| Sapropterin Dihydrochloride | 16 | $158,772 |
| CystadaneBetaine | 16 | $26,116 |
| LevocarnitineLevocarnitine (With Sugar) | 11 | $1,933 |
| Leucovorin Calcium | 13 | $499 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Biomarin Pharmaceutical Inc.Palynziq | $5,823 | $493,29513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 49 clinical genetics (m.d.) providers in New York.
Other clinical genetics (m.d.) in Bronx
- Susan GrossBronx$59
- Robert DesnickNew York$207K
- Manisha BalwaniNew York$188K
- David KronnValhalla$135K
- Jaya GaneshNew York$65K
- Berrin MonteleoneMineola$50K
- George DiazNew York$44K
- Christopher CunniffNew York$25K
- David BeckNew York$21K
- Kimihiko OishiNew York$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.